Literature DB >> 33333077

Structural analysis of prolines and hydroxyprolines binding to the l-glutamate-γ-semialdehyde dehydrogenase active site of bifunctional proline utilization A.

Ashley C Campbell1, Alexandra N Bogner1, Yizi Mao2, Donald F Becker2, John J Tanner3.   

Abstract

Proline utilization A (PutA) proteins are bifunctional proline catabolic enzymes that catalyze the 4-electron oxidation of l-proline to l-glutamate using spatially-separated proline dehydrogenase and l-glutamate-γ-semialdehyde dehydrogenase (GSALDH, a.k.a. ALDH4A1) active sites. The observation that l-proline inhibits both the GSALDH activity of PutA and monofunctional GSALDHs motivated us to study the inhibition of PutA by proline stereoisomers and analogs. Here we report five high-resolution crystal structures of PutA with the following ligands bound in the GSALDH active site: d-proline, trans-4-hydroxy-d-proline, cis-4-hydroxy-d-proline, l-proline, and trans-4-hydroxy-l-proline. Three of the structures are of ternary complexes of the enzyme with an inhibitor and either NAD+ or NADH. To our knowledge, the NADH complex is the first for any GSALDH. The structures reveal a conserved mode of recognition of the inhibitor carboxylate, which results in the pyrrolidine rings of the d- and l-isomers having different orientations and different hydrogen bonding environments. Activity assays show that the compounds are weak inhibitors with millimolar inhibition constants. Curiously, although the inhibitors occupy the aldehyde binding site, kinetic measurements show the inhibition is uncompetitive. Uncompetitive inhibition may involve proline binding to a remote site or to the enzyme-NADH complex. Together, the structural and kinetic data expand our understanding of how proline-like molecules interact with GSALDH, reveal insight into the relationship between stereochemistry and inhibitor affinity, and demonstrate the pitfalls of inferring the mechanism of inhibition from crystal structures alone.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALDH4A1; Enzyme inhibition; Proline metabolism; X-ray crystallography; l-glutamate-γ-semialdehyde dehydrogenase

Mesh:

Substances:

Year:  2020        PMID: 33333077      PMCID: PMC7856085          DOI: 10.1016/j.abb.2020.108727

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  35 in total

1.  electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation.

Authors:  Nigel W Moriarty; Ralf W Grosse-Kunstleve; Paul D Adams
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-09-16

2.  Looking for protein stabilizing drugs with thermal shift assay.

Authors:  Giuseppina Andreotti; Maria Monticelli; Maria Vittoria Cubellis
Journal:  Drug Test Anal       Date:  2015-04-05       Impact factor: 3.345

3.  Structures of Proline Utilization A (PutA) Reveal the Fold and Functions of the Aldehyde Dehydrogenase Superfamily Domain of Unknown Function.

Authors:  Min Luo; Thameesha T Gamage; Benjamin W Arentson; Katherine N Schlasner; Donald F Becker; John J Tanner
Journal:  J Biol Chem       Date:  2016-09-27       Impact factor: 5.157

4.  Covalent Modification of the Flavin in Proline Dehydrogenase by Thiazolidine-2-Carboxylate.

Authors:  Ashley C Campbell; Donald F Becker; Kent S Gates; John J Tanner
Journal:  ACS Chem Biol       Date:  2020-03-18       Impact factor: 5.100

5.  Mechanism of inhibition for N6022, a first-in-class drug targeting S-nitrosoglutathione reductase.

Authors:  Louis S Green; Lawrence E Chun; Aaron K Patton; Xicheng Sun; Gary J Rosenthal; Jane P Richards
Journal:  Biochemistry       Date:  2012-02-28       Impact factor: 3.162

6.  How good are my data and what is the resolution?

Authors:  Philip R Evans; Garib N Murshudov
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-06-13

7.  Kinetic and structural characterization of tunnel-perturbing mutants in Bradyrhizobium japonicum proline utilization A.

Authors:  Benjamin W Arentson; Min Luo; Travis A Pemberton; John J Tanner; Donald F Becker
Journal:  Biochemistry       Date:  2014-07-30       Impact factor: 3.162

8.  Polder maps: improving OMIT maps by excluding bulk solvent.

Authors:  Dorothee Liebschner; Pavel V Afonine; Nigel W Moriarty; Billy K Poon; Oleg V Sobolev; Thomas C Terwilliger; Paul D Adams
Journal:  Acta Crystallogr D Struct Biol       Date:  2017-02-01       Impact factor: 7.652

9.  Structural Basis for the Substrate Inhibition of Proline Utilization A by Proline.

Authors:  David A Korasick; Travis A Pemberton; Benjamin W Arentson; Donald F Becker; John J Tanner
Journal:  Molecules       Date:  2017-12-23       Impact factor: 4.411

10.  Mechanistic and structural understanding of uncompetitive inhibitors of caspase-6.

Authors:  Christopher E Heise; Jeremy Murray; Katherine E Augustyn; Brandon Bravo; Preeti Chugha; Frederick Cohen; Anthony M Giannetti; Paul Gibbons; Rami N Hannoush; Brian R Hearn; Priyadarshini Jaishankar; Cuong Q Ly; Kinjalkumar Shah; Karen Stanger; Micah Steffek; Yinyan Tang; Xianrui Zhao; Joseph W Lewcock; Adam R Renslo; John Flygare; Michelle R Arkin
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

View more
  3 in total

1.  Structure-affinity relationships of reversible proline analog inhibitors targeting proline dehydrogenase.

Authors:  Alexandra N Bogner; John J Tanner
Journal:  Org Biomol Chem       Date:  2022-01-26       Impact factor: 3.876

Review 2.  Aldehyde Dehydrogenase 2 as a Therapeutic Target in Oxidative Stress-Related Diseases: Post-Translational Modifications Deserve More Attention.

Authors:  Jie Gao; Yue Hao; Xiangshu Piao; Xianhong Gu
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

3.  Structural basis for the stereospecific inhibition of the dual proline/hydroxyproline catabolic enzyme ALDH4A1 by trans-4-hydroxy-L-proline.

Authors:  Alexandra N Bogner; Kyle M Stiers; Cole M McKay; Donald F Becker; John J Tanner
Journal:  Protein Sci       Date:  2021-06-04       Impact factor: 6.993

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.